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Effects of Intensive Blood Pressure 
Reduction on Acute Intracerebral 
Hemorrhage: A Systematic Review 
and Meta-analysis
Shun Gong1,2, Chao Lin3, Danfeng Zhang1, Xiangyi Kong4,5, Jigang Chen1, Chunhui Wang1, 
Zhenxing Li1, Rongbin Chen1, Ping Sheng1, Yan Dong1 & Lijun Hou1
Current opinions about the effect of intensive blood pressure (BP) reduction for acute intracerebral 
hemorrhage (ICH) are inconsistent. We performed a meta-analysis to evaluate the efficacy and safety 
of intensive BP reduction for acute ICH by analyzing data from several recent randomized controlled 
trials (RCTs). There were six eligible studies that met the inclusion criteria, for a total of 4,385 acute ICH 
patients in this meta-analysis. After analyzing these data, we found differences between intensive and 
standard BP lowering treatment groups in total mortality rates, unfavorable outcomes, hematoma 
expansion, neurologic deterioration, and severe hypotension were not significant. Moreover, compared 
with the standard treatment, the rate of renal adverse event in intensive treatment group was 
significantly higher. The intensive treatment approach was recommended in the following situations: 
(1) longer prehospital duration; (2) lower National Institute of Health stroke scale (NIHSS) score; (3) no 
hypertension history.
Intracerebral hemorrhage (ICH) accounts for 10–15% of all strokes around the world every year1. ICH has been 
an important public health problem worldwide, with approximately a 50% case fatality at 30 days and high mor-
bidity in survivors1–3. The acute hypertensive response in ICH is highly prevalent and is an important prognostic 
factor4. To date, management of blood pressure (BP) has been proven to be safe, but remains uncertain as a 
method for improving clinical outcomes5–7.
The American Heart Association (AHA) previously suggested a target systolic BP of 140 to 179 mm Hg for 
patients with acute ICH3; reducing systolic BP to 140 mm Hg was currently recommended based on a large ran-
domized controlled trial (RCT)8. Several RCTs have attempted to illustrate the effects of intensive reduction of 
elevated BP on the outcomes of patients with ICH9–12. Although intensive BP reduction, (defined as a target 
systolic BP of 110 to 139 mm Hg), did not result in a lower rate of disability or death compared with an standard 
treatment (defined as a target systolic BP of 140 to 179 mm Hg). Intensive BP reduction has been demonstrated 
to be associated with beneficial effects of reducing hematoma growth and improving functional outcomes10, 11. 
Other studies and meta-analyses also revealed that intensive BP lowering was safe and might have the potential to 
improve outcomes and reduce hematoma expansion, but these findings did not reach statistical significance12–16. 
Hence, there is a dispute over how to guide the choice of a target systolic BP when treating acute hypertensive 
response in patients with ICH.
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Therefore, the purpose of this manuscript is to perform a comprehensive systematic review and meta-analysis 
to evaluate the efficacy and safety of intensive BP lowering compared with standard BP lowering.
Results
Description of the selection process. An initial search produced 4,511 results in Embase, 329 results in 
Pubmed, 154 results in Cochrane, 585 results in Essential Evidence, and 4,520 results in Scopus. There were 4,879 
results left after removing the duplicates. We excluded 2,761 results without original data and 1,493 results of case 
report through analysis of the abstracts. One additional article was selected from the reference lists of retrieved 
articles. The remaining 626 full-text articles were assessed for eligibility through an in-depth reading of the full 
text content of each article. Articles not meeting inclusion criteria were excluded: 355 articles without original 
data, 143 articles without concerned diseases, 66 articles not about BP reduction, 43 articles without control 
group, 8 articles without interest outcome, and 5 articles without valid data. The final 6 remaining articles are 
included in this meta-analysis (Fig. 1)9–12, 17, 18.
Description of included studies. Sample sizes of these 6 studies ranged from 25 to 2,839 subjects, with 
a total of 4,385 subjects. Subject mean age was 63.2 years, and were 62.9% male. Other characteristics of the 
included studies are summarized in Table 1. Risk of bias of included studies is available in Fig. 2.
Figure 1. Preferred reporting items for systematic reviews and meta-analyses 2009 flow diagram.
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Primary outcomes. Mortality. The mortality rates had been reported in all 6 studies. After testing for het-
erogeneity, there was no statistical heterogeneity among these 6 trials (Chi-square = 1.37, I2 = 0%, P = 0.93). Our 
findings indicated that intensive treatment was not associated with a reduction in the mortality rate compared 
with standard treatment (P = 0.85). The Odds ratio (OR) values in these 6 trials ranged from 0.81 to 2.27, with an 
overall OR of 0.98 (95% CI: 0.81–1.19; Fig. 3A).
Unfavorable outcomes. Five studies with 3,300 patients analyzed the unfavorable outcomes between the inten-
sive and standard treatment groups. The heterogeneity among these 5 studies was low (Chi-square = 5.09, 
I2 = 21%, P = 0.28). Pooled OR of unfavorable outcomes was 0.95 (95% CI: 0.80–1.13) and the incidence of unfa-
vorable outcomes was not statistically significantly different between the intensive and standard treatment groups 
(P = 0.59; Fig. 3B).
Secondary outcomes. Hematoma expansion at 2 hours. Five studies with 2,852 patients discussed 
hematoma expansion (HE) at 24 hours. Heterogeneity among these trials was low (Chi-square = 5.44, I2 = 27%, 
P = 0.24). The overall OR was 0.83 (95% CI: 0.65–1.07), showing that the incidence of HE was not significantly 
different in the intensive vs standard treatment group (P = 0.16; Fig. 4A).
Neurologic deterioration. Four studies with 4,308 acute ICH patients compared the ratio of neurological dete-
rioration. For the heterogeneity, I2 value was 21% with P = 0.29. The pooled OR and 95% CI of neurological 
deterioration was 1.03 (95% CI: 0.76–1.40), showing that the difference between intensive treatment and standard 
treatment was not significant (P = 0.86; Fig. 4B).
Severe hypotension. Three studies with 4,233 patients were available for the analysis of severe hypotension. 
Heterogeneity among trials was low (Chi-square = 1.14, I2 = 0%, P = 0.56). The pooled OR was 1.08 (95% CI, 0.52 
to 2.19), indicating no significant difference between two groups (P = 0.87; Fig. 4C).
Pooled adverse event of BP reduction. We evaluated the occurrence of an adverse event (AE) asso-
ciated with BP reduction. Events included: cardiovascular, renal, recurrent stroke, and non-cardiovascular 
events (Table 2). The risk ratio (RR) of each AE occurrence were greater than 1.0 with heterogeneity of I2 < 30%. 
However, meta-analysis showed significant difference between two treatment approaches only for renal AE 
(P = 0.001). This indicated that the intensive treatment for acute ICH patients had higher risk of renal adverse 
effects than standard treatment. The P-values for the remaining RR were >0.05.
Subgroup analysis of unfavorable outcomes. We compared the unfavorable outcomes of various ICH 
subgroups based on age, history of hypertension, time from onset to randomization, baseline systolic BP, and 
National Institute of Health stroke scale (NIHSS) score at baseline.
Source
Sample size 
(Intensive/
Standard)
Hematoma volume (ml) 
(Intensive/Standard)
Sex 
(male)
Mean 
age 
(year)
Duration 
of 
fellow-up 
(month)
Baseline BP 
(mmHg) 
(Intensive/
Standard)
BP target 
in intensive 
group 
(mmHg)
BP 
target in 
standard 
group 
(mmHg) Outcomes Country
Jadad 
score
Anderson 
et al., 2008 203/201 14.2 ± 14.5/12.7 ± 11.6 64.9% 62.5 3 SBP: 180/182 SBP < 140 SBP < 180
Death or 
dependency, 
mRS, NIHSS, 
Barthel index, AE
Australia 4
Anderson 
et al., 2013 1403/1436 11/11 62.9% 63.5 3 SBP: 179/179 SBP < 140 SBP < 180
Death or 
dependency, 
mRS, AE, quality 
of life
Australia 5
Butcher et 
al., 2013 39/36 25.6 ± 30.84/26.9 ± 25.24 72% 69.7 3 SBP: 182/184 SBP < 150
SBP: 
150–180
Mortality, mRS, 
Barthel Index Canada 3
Koch et al., 
2008 21/21 12.5 ± 17.2/8.5 ± 9.8 54.8% 60.6 3 MAP: 144/151 MAP < 110
MAP: 
110–130 Mortality, mRS USA 3
Potter et 
al., 2009 18/7 — 55.2% 74 3 SBP: 182/181 SBP: 145–155 SBP > 155
Dead or 
dependent, mRS, 
AE
UK 3
Qureshi et 
al., 2016 500/500 10.3/10.2 62% 61.9 3 SBP: 200/201 SBP: 110–139
SBP: 
140–179
Death or 
dependency, 
mRS, AE, EQ-
5D, NIHSS
USA 5
Table 1. Design and patient characteristics for studies included in the meta-analysis. Abbreviations: AE: 
adverse event; mRS: Modified Rankin Scale; NIHSS: National Institute of Health stroke scale; BP: blood 
pressure; SBP: systolic blood pressure; MAP: mean arterial pressure; EQ-5D: European Quality of Life-
5Dimensions.
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Age. Data from 2 studies was stratified and analyzed based on different age stages (≤65 years old subgroup, and 
>65 years old subgroup). There was no significant difference on unfavorable outcomes for the age ≤65-year-old 
subgroup (OR = 0.84, 95% CI: 0.67–1.05, P = 0.13); nor for the age >65-year-old subgroup (OR = 0.86, 95% CI: 
0.65–1.15, P = 0.32) (Fig. 5).
History of hypertension. We stratified subgroups by hypertension history (Fig. 5). In patients with a history 
of hypertension, the summary OR was 0.92 with P of 0.37. However, in patients without a history of hyperten-
sion, the incidence of unfavorable outcomes in intensive treatment group was significantly lower than standard 
treatment group with a pooled OR of 0.68 (95% CI: 0.53–0.89, P = 0.004). These data suggest that the intensive 
treatment approach was a prior selection in acute ICH patients without hypertension history.
Figure 2. (A) Risk of bias graph; (B) Risk of bias summary.
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Time from onset to randomization. The time periods from onset to randomization were defined as shorter pre-
hospital duration subgroup and longer prehospital duration subgroup according to the original data in included 
studies. In the shorter prehospital subgroup, overall OR value was not significant (OR = 0.66, P = 0.35). In the 
longer prehospital duration subgroup, the incidence of unfavorable outcomes in intensive treatment group was 
significantly lower than standard treatment group with a pooled OR of 0.80 (95% CI: 0.64–0.99, P = 0.04; Fig. 5).
Baseline of systolic BP. Baseline systolic BP was divided into two subgroups based on the level of 180 mm Hg. 
Neutral results (P > 0.05) were found for both subgroups analysis (Fig. 5). Hence, it appears to be unnecessary to 
take baseline systolic BP into account when selecting a treatment schedule.
Figure 3. Forest plot of the comparison between intensive treatment and standard treatment: Primary 
outcomes: (A) Mortality; (B) Unfavorable outcomes.
Figure 4. Forest plot of the comparison between intensive treatment and standard treatment: Secondary 
outcomes: (A) Hematoma expansion; (B) Neurologic deterioration; (C) Severe hypotension.
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NIHSS score at baseline. Subgroup analysis was stratified by NIHSS score (lower NIHSS score subgroup and 
higher NIHSS score subgroup). In the lower NIHSS score subgroup, the pooled OR value was 0.83 (P = 0.03), sug-
gesting the significantly lower incidence of unfavorable outcomes in intensive treatment group than in standard 
treatment group. In the higher NIHSS score subgroup, we didn’t find any significant difference (Fig. 5).
Discussion
The present meta-analysis of 6 RCTs and 4,385 acute ICH patients explored the influence of systolic BP reduction 
on acute ICH outcomes. Our results demonstrated that the differences of primary outcomes (mortality and unfa-
vorable outcomes) and secondary outcomes (HE at 24 hrs, neurologic deterioration, severe hypotension) were not 
significant between the intensive treatment group and standard treatment group. Moreover, the risk of renal AE in 
intensive treatment was significantly higher compared with standard treatment. Most importantly, the subgroup 
analysis found that the acute ICH patients treated using an intensive approach had lower rate of unfavorable out-
comes for patients with no history of hypertension, or longer prehospital duration, or lower NIHSS score.
There were four meta-analyses published previously14–16, 19. Of these, only one meta-analysis that included four 
RCTs found a significant association between intensive BP lowering and reduction of hemorrhage expansion asso-
ciated with improved clinical functional outcome15. The other 3 meta-analyses were consistent with our findings 
in that they detected no significant relationships between intensive treatment and poor clinical outcomes14, 16, 19. 
Notably, we found for the first time that selected patients with no history of hypertension, or longer prehospital 
duration, or lower NIHSS score might benefit from intensive BP lowering therapy.
Most of the observational studies found a tight association between BP and HE in patients with acute 
ICH20, 21. Improving clinical outcomes with intensive BP reduction treatment was hypothesized to be related to 
reduce HE22. It was speculated that intensive BP reduction improved outcomes through attenuation of absolute 
hematoma volume increasing at 24 hrs before and after adjustment for potential confounders15, 23. In addition, 
researchers found intensive BP reduction did not increase the volume of critically hypoperfused border-zone 
or perihematoma tissue, which supporting the safety of intensive BP reduction in acute ICH24. However, other 
studies did not find an association between BP and HE within the first 24 hrs14, 25. Therefore, as previously demon-
strated, there remained doubtful as to the association of benefit from intensive treatment of BP for clinical out-
comes in ICH.
Research has indicated that renal dysfunction is associated with intensive BP reduction after acute ICH26, 27. In 
a randomized pilot trial (INTERACT), renal failure was reported in 2% of acute ICH patients following intensive 
BP reduction11. Qureshi et al.9 reported that the rate of renal AE within 7 days was significantly lower in the stand-
ard treatment than intensive treatment. Consistent with the previous results, our meta-analysis results showed 
the pooled renal AE associated with BP reduction in intensive treatment had higher RR. As patients with renal 
failure have significantly worse outcomes in acute ICH, intensive BP lowering provides similar treatment effects 
irrespective of degree of renal failure28. Given that because the kidney contains many small vessels; severe hyper-
tension usually leads to renal arteriolar sclerosis and hypotension also causes renal blood perfusion inadequacy 
and then renal failure. So, we speculate that intensive BP lowering contributes to higher RR of renal AE because 
of the hypertension before treatment and subsequent hypotension after treatment. Therefore, it is essential to 
carefully monitor the renal function in reducing systolic BP for acute ICH patients, especially for those with a 
history of hypertension.
In our subgroup analysis, results showed that the acute ICH patients treated by intensive approach had lower 
rate of unfavorable outcomes in subgroups of with no history of hypertension, or longer prehospital duration, 
or lower NIHSS score. These findings were the first to reported and might play an important role in choosing 
an appropriate therapeutic approach for selected patients. However, Anderson et al.10 found no significant effect 
of hypertension history on the effectiveness of intensive treatment. The possible reason was that patients with 
hypertension had an upward shift in cerebral autoregulation and possibly underwent increased risk of cerebral 
ischemia related to intensive BP lowering29. In the present study, subgroup analysis of onset age and the sys-
tolic BP at baseline of acute ICH patients was not significant. However, the INTERACT2 cohort30 detected that 
older people had more severe acute ICH status and worse outcomes (mortality, disability and quality of life). 
Moreover, the subgroup analysis of time from onset to randomization and NIHSS score baseline indicated that 
selected patients with longer prehospital duration or lower baseline NIHSS score might benefit from intensive 
treatment. This might be due to that longer prehospital duration led to progressive deterioration of HE, which 
would be more sensitive to intensive BP lowering. In contrast, patients with shorter prehospital duration might 
differ in the degree of damage. Therefore, the effectiveness of standard treatment and intensive treatment could 
not be differentiated, and need to be identified by further study with similar brain injury. Patients with lower 
NIHSS score might suffer mild brain damage, and thus benefit much from intensive BP lowering by saving more 
Adverse effects(AE)
Number of 
studies
Number of patients 
Intensive/Standard
Risk ratio (RR) 
and 95%CI P-value I2 (%)
cardiovascular AE 3 86 / 77 1.09 [0.72, 1.66] 0.67 28
renal AE 2 49 / 22 2.34 [1.39, 3.92] 0.001 0
recurrent stroke 3 50 / 48 1.05 [0.69, 1.58] 0.83 0
non-cardiovascular AE 2 177 / 173 1.05 [0.84, 1.31] 0.68 0
Table 2. Pooled risk ratios of adverse effects of blood pressure reduction in included studies.
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perihematoma tissue. While patients with higher NIHSS would suffer severe brain damage and thus BP lowering 
might be not helpful, for whom surgery would be an alternative treatment.
There are several limitations to this analysis. First, in any meta-analysis, publication bias is always considered 
as a major potential threat to validity31. We minimized the risk of publication bias through our extensive and 
careful retrieval. Second, we included 3 RCTs with relative small samples and low quality. Third, in our subgroup 
analysis, we included only 2 RCTs for each subgroup, which reduced the statistical power to detect a difference. 
Fourth, the different research outcomes may be influenced by either observer bias or selection bias, even though 
three authors (S.G., C.L., D.F.Z.) selected papers with strict inclusion criteria and exclusion criteria, the bias had 
more or less effect on the results and conclusion. Hence, high quality and large sample size RCTs are needed to 
confirm these results.
Figure 5. Forest plot of the subgroup analysis of unfavorable outcomes compared between intensive treatment 
and standard treatment.
www.nature.com/scientificreports/
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Methods
Research protocol. This study was performed according to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines32, and the protocol of this meta-analysis has not been previously 
registered.
Types of outcome measurements. We evaluated the following outcomes: a) mortality rates; b) unfavora-
ble outcomes (defined as a modified Rankin Scale score of 4–6); c) hematoma expansion; d) neurologic deteriora-
tion (defined as an increase from baseline to 24 hours of 4 or more points on the NIHSS or a decrease of 2 or more 
points on the Glasgow Coma Scale); e) severe hypotension; f) adverse events.
Inclusion and exclusion criteria. Studies were included if they were RCTs meeting the following criteria: a) 
including patients (more than 18 years old and both genders) with radiologically confirmed ICH; b) randomizing 
patients to either the intensive BP lowering treatment group or standard BP lowering treatment group; c) meas-
uring the outcomes we listed above; d) being sufficient to allow calculation of effect sizes.
Studies were excluded if they included one of the following circumstances: a) patients who had serious cardi-
ovascular diseases, cancers, and other visceral functional diseases; b) age of participants were less than 18 years 
old; c) studies without the previous definition of outcomes or the variables were different from our measurements.
Literature search strategies. We conducted a search of sufficient rigor in the literature library of: Embase, 
PubMed, Scopus, Cochrane library, and Essential Evidence from 1980 to August 2016. The search included a 
combination of the free words ‘intracranial hemorrhage’ and ‘blood pressure’, or the key words ‘intracerebral 
hemorrhage’ and ‘blood pressure’. No language or other restrictions were imposed. The search strategies were 
showed in detail in Fig. 1. We have checked reference lists of all articles that met the criteria and examined rele-
vant review articles to identify studies that may have been missed in the database search.
Study selection and data collection process. Three authors (S.G., C.L. and D.F.Z.) independently 
searched and read the titles, abstracts and full text of literatures obtained from electronic databases and excluded 
studies that were irrelevant to our object. The authors discussed and resolved the disputes together. Z Li, R Chen 
and P Sheng extracted the following data from included studies independently: the name of first author, publica-
tion year and country of each literature, the sample size of intensive and standard treatment group, ratio of sex, 
mean age, duration of follow-up (months), outcomes, baseline and target BP level of both groups (Table 1).
Statistical analysis and quality assessment. We conducted this meta-analysis using Review Manager 
version 5.2 software (http://tech.cochrane.org/revman). ORs and RRs were used to express the comparison 
between intensive BP reduction and standard BP reduction in acute ICH patients. Heterogeneity among studies 
was assessed by the I2 statistics. Higher values of I2 indicated greater degree of heterogeneity. The value of I2 ≤ 50% 
denoted acceptable heterogeneity among studies, with I2 > 50% were considered to suggest substantial hetero-
geneity, while values I2 ≥ 75% indicated considerable heterogeneity33, 34. Random-effect model was used in data 
synthesis process. In order to maximize the power of the test, Egger test was conducted to assess the publication 
bias. Risk of bias of included studies were assessed based on the recommendation of Cochrane Collaboration, 
including selection bias, performance bias, detection bias, attrition bias and reporting bias.
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